[go: up one dir, main page]

WO2023133424A3 - Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides - Google Patents

Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides Download PDF

Info

Publication number
WO2023133424A3
WO2023133424A3 PCT/US2023/060117 US2023060117W WO2023133424A3 WO 2023133424 A3 WO2023133424 A3 WO 2023133424A3 US 2023060117 W US2023060117 W US 2023060117W WO 2023133424 A3 WO2023133424 A3 WO 2023133424A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion
methods
fusion peptides
tfps
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/060117
Other languages
French (fr)
Other versions
WO2023133424A2 (en
Inventor
Vania E. Ashminova
Michael Lofgren
Dana GILMORE
Derrick Mccarthy
Dario Gutierrez
Michelle FLEURY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TCR2 Therapeutics Inc
Original Assignee
TCR2 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TCR2 Therapeutics Inc filed Critical TCR2 Therapeutics Inc
Publication of WO2023133424A2 publication Critical patent/WO2023133424A2/en
Publication of WO2023133424A3 publication Critical patent/WO2023133424A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides T-cell (receptor) fusion proteins (TFPs) comprising binding domains targeting various antigens associated with a disease or nucleic acid molecules encoding such TFPs. The present disclosure also provides anti-PD-1 fusion peptides, as well as nucleic acids molecules encoding the anti-PD-1 fusion peptides. The present disclosure further provides modified T cells expressing such TFPs or the anti-PD-1 fusion peptides, and methods of regulating T cells or treating patients using such constructs or modified T cells.
PCT/US2023/060117 2022-01-05 2023-01-04 Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides Ceased WO2023133424A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263296656P 2022-01-05 2022-01-05
US63/296,656 2022-01-05
US202263354450P 2022-06-22 2022-06-22
US63/354,450 2022-06-22

Publications (2)

Publication Number Publication Date
WO2023133424A2 WO2023133424A2 (en) 2023-07-13
WO2023133424A3 true WO2023133424A3 (en) 2023-09-07

Family

ID=87074264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060117 Ceased WO2023133424A2 (en) 2022-01-05 2023-01-04 Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides

Country Status (1)

Country Link
WO (1) WO2023133424A2 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488802B2 (en) * 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
US8735553B1 (en) * 2013-09-13 2014-05-27 Beigene, Ltd. Anti-PD1 antibodies and their use as therapeutics and diagnostics
WO2020023888A2 (en) * 2018-07-26 2020-01-30 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using target specific fusion proteins
US20200140512A1 (en) * 2018-10-12 2020-05-07 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US20210070887A1 (en) * 2019-06-25 2021-03-11 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
WO2021119429A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
US20210187022A1 (en) * 2016-12-21 2021-06-24 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
US20210355185A1 (en) * 2019-10-03 2021-11-18 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488802B2 (en) * 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
US8735553B1 (en) * 2013-09-13 2014-05-27 Beigene, Ltd. Anti-PD1 antibodies and their use as therapeutics and diagnostics
US20210187022A1 (en) * 2016-12-21 2021-06-24 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
WO2020023888A2 (en) * 2018-07-26 2020-01-30 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using target specific fusion proteins
US20200140512A1 (en) * 2018-10-12 2020-05-07 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US20210070887A1 (en) * 2019-06-25 2021-03-11 Gilead Sciences, Inc. FLT3L-Fc FUSION PROTEINS AND METHODS OF USE
US20210355185A1 (en) * 2019-10-03 2021-11-18 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
WO2021119429A1 (en) * 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
WO2021232200A1 (en) * 2020-05-18 2021-11-25 Guangdong Tcrcure Biopharma Technology Co., Ltd. Il-12 armored immune cell therapy and uses thereof

Also Published As

Publication number Publication date
WO2023133424A2 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
WO2022006451A3 (en) Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
JP6849600B6 (en) Chimeric antigen receptor, composition and method
CN118634339B (en) Targeted ligand-payload based drug delivery for cell therapy
WO2005089285A3 (en) Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
PL393644A1 (en) Host cell, method for producing a polypeptide in a host cell, antibody, antibody fragment, protein fusion, a pharmaceutical composition and method for treating cancer
NO20020861D0 (en) PD-1, a receptor for B7-4, and uses thereof
AU7599500A (en) Novel gl50 molecules and uses therefor
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
CN109803679A (en) Production of selenobiologics in genome-recoded organisms
MX2022013894A (en) Neutralizing antibodies that bind the sars-cov-2 s protein.
WO2021133959A3 (en) Compositions and methods for gamma delta tcr reprogramming using fusion proteins
Teal et al. Directed evolution enables simultaneous controlled release of multiple therapeutic proteins from biopolymer‐based hydrogels
WO2021226289A3 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
Trimmer Genetically encoded intrabodies as high-precision tools to visualize and manipulate neuronal function
Purde et al. Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts
MX2022002984A (en) Compositions and methods for tcr reprogramming using fusion proteins.
Zong et al. Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2023150724A3 (en) Antigen binding proteins that bind b7-h3
WO2023133424A3 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
CN112955184A (en) Programmable immune cell receptor complex system
EP1127133B1 (en) Polypeptide mediating cell permeability
CN106967173A (en) The chimeric memebrane protein of one kind restructuring and its preparation and application
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23737723

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23737723

Country of ref document: EP

Kind code of ref document: A2